The real promise of improving patient outcomes in IgD and IgE multiple myeloma lies in multi-drug combinations, next-generation agents, and immunotherapy.
Claudia Paba-prada, MD
Advertisement
Articles by Claudia Paba-prada, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Melanoma Vaccine Receives FDA Fast Track Designation
2
Targeting NAMPT and KRAS in Pancreatic Ductal Adenocarcinoma
3
NCCN Guidelines Recommend Taletrectinib for ROS1+ NSCLC Subtype
4
Duvelisib Shows Significant Activity in R/R Peripheral T-Cell Lymphoma
5